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Abstract
Background In 2003, for the first time, US breast cancer
incidence rates have fallen. Experts argue whether this is
due to the reduced uptake of screening mammography or to
lower use of Hormone Replacement Therapy (HRT). This
study aims to disentangle the respective impact of screen-
ing and HRT on age-incidence rates and histology of breast
cancer, by comparing two populations with comparably
high levels of screening mammography, but with different
prevalence of HRT.
Methods We included all invasive breast cancers recorded
at the Geneva cancer registry (n = 4,909) and the Netherlands
Cancer Registry (n = 152,428) between 1989–2003. We
compared age-specific incidence rates and trends in histo-
logical subtyping between the two populations.
Results Between 1989–1991, incidence rates increased
with age in both populations. In 2001–2003, women aged
60–64 years showed highest incidence rates in Geneva,
while in the Netherlands incidence rates continued to in-
crease with age. The annual increase in ductal cancer
incidence was similar in the Netherlands (2.3%) and
Geneva (2.5%), but the annual increase in lobular cancer
was sharper in Geneva (10%) than in the Netherlands (5%).
Conclusion The sharp differences in age distribution and
histological subtyping of breast cancer between two
European populations are not attributable to screening,
since both populations have a high uptake of mammogra-
phy screening. Since the prevalence of HRT use is very
high in Geneva and rather low in the Netherlands, HRT
may explain these discrepancies. However, other etiologi-
cal factors and differences in histological assessment may
also have played a role.
Keywords Breast cancer  Hormone replacement
therapy  Incidence  Population-based  Screening
Introduction
In 2003, for the first time in recent history, the incidence of
breast cancer has come down in the United States [1].
Experts argue whether this is due to the lower uptake of
screening mammography following publications questioning
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its effectiveness [2, 3] or because of the decreased use of
Hormone Replacement Therapy (HRT) following reports on
its association with increased breast cancer and cardiovas-
cular risks [4, 5]. Other reasons, including other medications
potentially linked to breast cancer risk, may have influenced
breast cancer rates as well.
Within Europe, there are large disparities in uptake of
screening mammography and prevalence of HRT use. This
provides unique opportunities for ecological studies on the
respective impact of screening and HRT on breast cancer
incidence trends.
Over recent years, several studies have reported changes
in breast cancer incidence, including increasing incidence
rates, shifts in age distribution of breast cancer and
disproportionate rises in lobular cancer rates. In many
European countries, incidence rates of invasive breast
cancer have increased sharply following the introduction of
organized screening programs [6–8]. In addition, there
have been changes in age-distribution of breast cancer.
Classically, the risk of breast cancer increases with age, but
reports from the United States, Switzerland, Finland,
Denmark and Sweden [9–13] have shown that this classical
pattern is changing. In these populations, highest rates are
no longer observed among older women, but among
women in their early sixties. Mechanisms for this shift are
not yet well understood. Recently, we published popula-
tion-based data from the Swiss canton of Geneva which
was highly suggestive of a key role of hormone replace-
ment therapy (HRT) in the change in age-specific breast
cancer incidence [9]. This study contradicted those of
Hemminki et al. who attributed the change in age-inci-
dence rates in Sweden and other European countries to the
use of mammography screening [12, 13].
In parallel with the shift in age-specific incidence in
several countries, invasive lobular cancer rates have in-
creased sharply, particularly during the nineties [14–17].
The increasing use of HRT during the eighties and nineties
has been proposed as the reason of the increase in lobular
cancer incidence [18–20]. Nevertheless, improved diag-
nostic techniques, increased diagnostic activity (screening)
and changes in criteria for histological assessment may also
have played a role.
In the current study, we compare trends in incidence rates,
age-specific incidence rates and histological subtyping of
breast cancer between Geneva Switzerland and the Nether-
lands. Both populations have breast cancer rates that are
among the highest in the world [21]. Both countries have a
high standard of medical care and large proportions of wo-
men undergoing organized or opportunistic mammography
screening [8, 22]. The prevalence of HRT during the nineties
was, however, quite different. In the Netherlands, 13% of all
49–70 year old women and 19% of the 49–54 year old wo-
men were current users of HRT between 1993–1997 [23]. In
Geneva, the prevalence of HRT use is particularly high. In
1996, more than 50% of 45–59 year old women were current
users of HRT [24]. A more recent study showed that in 2002,
46% of all women between 35 and 74 years were current
users of HRT and the average duration of use was 7.8 years
[25]. The proportion of current users in the 45–59 year old
age group would probably have been much higher.
Materials and methods
For this study, we used data from two population-based
cancer registries: the Netherlands Cancer Registry and the
Geneva Cancer Registry.
Nationwide cancer registration in the Netherlands star-
ted in 1989. The Netherlands Cancer Registry consists of
nine regional registries of the Comprehensive Cancer
Centres in the Netherlands. It collects data on all malignant
neoplasms in the Dutch population. Population data of the
Netherlands were obtained from Statistics Netherlands
(Central Bureau voor de Statistiek [CBS] Voorburg /
Heerlen, the Netherlands). During the study period, the
total population of the Netherlands increased from 15 to
16 million persons.
The Geneva Cancer Registry collects information on all
incident cases of cancer in the Swiss canton of Geneva
since 1970. Populational data for the canton of Geneva
were obtained from the Cantonal Population Office (Office
Cantonal de la Population) which covers a population of
approximately 420,000 inhabitants.
Both cancer registries are notified by pathologists and
medical registration offices on the occurrence of every
incident case of cancer. Trained registry staff actively
retrieves relevant information, using information from
medical records and pathology reports. Recorded data in-
clude socio-demographic characteristics and tumour char-
acteristics coded according to the International
Classification of Diseases for Oncology (ICD-O) and stage
at diagnosis [26].
In both populations, we identified all incident cases of
invasive breast carcinoma (ICD code 174) diagnosed
between 1989 and 2003. Women with pure in situ lesions
(ductal carcinoma in situ or lobular carcinoma in situ) were
excluded. Histologic review of microscopic slides was not
performed.
Breast cancers were classified as ductal carcinoma
(ICD-O code 8500), lobular carcinoma (lobular IDC-O
code 8520 and 8522) and other (all other cancers including
those without microscopic confirmation).
Incidence rates (European age-standardized) according
to histological subtype were calculated. Variations in
incidence rates were studied by generalised linear regres-
sion analyses based on the maximum likelihood method
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[27]. Age-specific incidence rates were calculated by
5-years age groups and compared between two periods
(1989–1991 and 2001–2003).
Results
Between 1989 and 2003, 152,428 Dutch women and 4909
women from Geneva, Switzerland were diagnosed with
invasive breast cancer. In both populations, there was a
significant increase in breast cancer incidence: in the
Netherlands, the incidence (European age-standardised)
went from 105 to 126/100,000 and the average annual in-
crease was 1.3% (P < 0.05) (Fig. 1). In Geneva, Switzerland,
the incidence went from 114 to 150/100,000 and the increase
was 2.4% (P < 0.001) per year.
In the early years of the study period (1989–1991), age-
specific incidence increased with age in both populations
and highest rates were observed among the 80–84 years old
in the Netherlands and among women older than 85 years
in Geneva (Fig. 2 panel A).
Between 2001 and 2003, the age distribution of breast
cancer was very different between the two populations
(Fig. 2 panel B). In Geneva, an incidence peak appeared
among women aged 60–64 years: breast cancer rates no
longer increased with age, but were highest in middle-aged
women and reduced in the elderly. The incidence rates for
women aged 60–64 years almost doubled and rose from
289/100,000 in 1989–1991 to 552/100,000 in 2001–2003.
For women older than 85 years, the breast cancer incidence
rates dropped from 425 to 323/100,000.
In 2001–2003, in the Netherlands, there was still the
classical pattern, with highest breast cancer rates in the
oldest age categories. Breast cancer rates for women aged
60–64 years increased moderately from 255/100,000 in
1989–1991 to 321/100,000 in 2001–2003. There was no
decrease in incidence among women older than 80 years.
In Geneva, 73% of the patients (3573) had ductal his-
tology, 11% (530) lobular histology and 16% (806) other
histological subtypes. In the Netherlands, 65% of the pa-
tients (98,962) had ductal cancer, 15% (22,112) had lobular
cancer and 21% (31,354) had other histological subtypes.
In the Netherlands, the invasive ductal cancer rates went
from 67 to 89/100,000 between 1989 and 2003 and the
average annual increase was 2.2% (P < 0.01) (Fig. 3, panel
A). In the same period in Geneva, the ductal cancer inci-
dence went from 87 to 116/100,000 between 1989 and
2003 and the average annual increase was 2.5%
(P < 0.001).
The trend in invasive lobular cancer incidence was
different between the two populations (Fig. 2, panel B). In
the Netherlands, the incidence of invasive lobular cancer
increased from 13 to 19/100,000 between 1989 and 2003
with a mean annual increase of 3.1% per year (P < 0.05).
In Geneva, the increase of invasive lobular cancer inci-
dence was much sharper (9.1% per year, P < 0.001) and
went from 7 to 20/100,000 between 1989 and 2003.
In the Netherlands, the incidence of other histological
subtypes decreased from 26 to 18/100,000 (mean annual
decrease of 3.2%, P < 0.01) and in Geneva from 21 to 14/
100,000 between 1989 and 2003 (mean annual decrease
3.0%, P < 0.05) (Fig. 3, panel C).
In Geneva, the increase in ductal cancer can be completely
attributed to an increase in incidence among 55–69 year old
women (Fig. 4 panel A). Especially for women aged
60–64 years, the ductal cancer incidence almost doubled and
increased from 225 to 432/100,000 between 1989–2003. In
the Netherlands, ductal cancer rates moderately increased in
all age categories after 45 years. Only for 75–79 year old
women there was a deficit of cases between 2001–2003, due
to intensive screening in previous age categories. In 2001–
2003, the absolute difference in ductal cancer rates between
Geneva and Dutch 60–64 year olds was eminent: 432 versus
234 /100,000 respectively.
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Also for lobular cancer, there were important differ-
ences in age distribution between the two populations
(Fig. 4, panel B). In Geneva, lobular incidence rates in-
creased sharply for women aged 50–74 years, whereas no
major changes occurred for women under 50 years and
those older than 80 years. Particularly sharp increases were
seen among women aged 60–74 years. In the Netherlands,
lobular incidence rates increased for all women after the
age of 45 years, and the highest lobular cancer incidence
increases were seen among the very old women. In
2001–2003, absolute differences in lobular cancer rates
between Genevese and Dutch women were most pro-
nounced for the age categories 60–64 years (76 versus 49/
100,000 respectively) and 85 years and older (11 versus
51/100,000 respectively).
In Geneva, the decrease in incidence of other histolog-
ical subtypes was mostly attributable to a sharp decrease
among the very old women (Fig. 4, panel C). In the
Netherlands, the incidence of other histological subtypes
decreased for all age categories to the same extent and in
2001–2003, Dutch and Genevese women had similar rates
of other histologies.
Discussion
In this study we have shown some intriguing differences in
age distribution and histological subtyping of breast cancer
between two populations with high incidence rates of
breast cancer. Firstly, there was a compelling shift in age
distribution of breast cancer incidence in Geneva, which
was completely absent in the Netherlands. Secondly, the
incidence of lobular cancer increased more sharply in
Geneva than in the Netherlands, while ductal cancer rates
increased to the same extent. The 10% increase in lobular
cancer in Geneva was due to a sharp increase in 50–74 year
olds, while in the Netherlands, lobular cancer incidence
increased more or less proportionately in all age groups
after 45 years. In Geneva, the 2.5% annual increase in
ductal cancer incidence was exclusively due to an almost
doubling of the incidence of 55–69 year olds, while in the
Netherlands, the 2.2% annual ductal cancer incidence in-
crease could be attributed to a proportionate increase in all
age categories after 45 years.
Some have advocated mammography screening as the
explanation of the shift in age-specific breast cancer rates
[12, 13]. Using the EUROCAN database, Hemminki and
Bermejo compared age-specific incidence rates in several
European countries with different attitudes towards, and
different levels of implementation of mammography
screening in the year 1995 [13]. They observed the typical
shift in age-incidence rates in countries with generalization
of screening mammography (including France, Sweden,
UK and, surprisingly, also the Netherlands), but not in
Germany, where organized and opportunistic screening is
nearly inexistent. They concluded that screening affects
age-incidence trends. They also showed that in Sweden,
Norway and Finland, the change in age-incidence rates was
progressive during the implementation of the screening
programs, suggesting a relation between mammographic
coverage and age distribution of breast cancer [13]. How-
ever, the changes continued to progress for at least several
years after full implementation of mammography screening
programs, rendering a key role of screening less likely.
The results of our study practically rule out that
screening mammography caused this dramatic change.
Screening mammography is very common in the Nether-
lands, where 80% of the target population (women aged
49–74 years) participate in the national screening program
[8]. In Geneva, the breast cancer screening program started
only in 1999 and has a relatively low participation rate of
approximately 20%. However, since the early nineties,
opportunistic screening is common in the canton of Geneva
and in the 1997 Swiss National Health Survey over 60% of
Geneva women reported to have undergone screening
mammography. Nevertheless, it is unlikely that the use of
screening mammography in Geneva exceeds the 80%
participation rate in the Netherlands. Consequently,
increasing use of screening mammography is not a plau-
sible explanation for the shift in age distribution of breast
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cancer, simply because this change did not occur in the
intensively screened population of the Netherlands.
This is supported by a recent study from Denmark,
which reported a similar change in age-incidence rates
among women who did not participate in the screening
program (80% of the Danish female population) [11]. Since
opportunistic screening also is uncommon in Denmark,
again, the change could simply not be attributed to mam-
mography screening.
Some studies evoked HRT as an explanation for the shift
in age-specific breast cancer rates. A study from Norway
among 45–60 year old women showed that, compared to
women who did not use HRT or mammography screening,
those who underwent screening mammography had a 20%
increased risk of having breast cancer diagnosed [28].
However, women who did not use mammography screen-
ing, but who were current users of HRT had a more than
doubled risk of being diagnosed with breast cancer.
In a previous study from Geneva, we demonstrated that
the changed incidence pattern, i.e. incidence ‘peak’ among
middle-aged women and deficit of breast cancer cases
among elderly women, was only present among women
who reported ever use of HRT, regardless whether their
tumor was screen detected or not [9].
We realize that the shift in age-incidence rates of breast
cancer is major and the association between living in
Geneva and using HRT must be very strong for it to ex-
plain the changes observed. However, HRT use in Geneva
is particularly prevalent. The proportion of current HRT
users among women aged 45–59 years increased from 34%
in 1993 to over 50% in 1996 [24]. More recently, Morabia
and Constanza [25] showed that in the first six months of
2002 46% of all women between 35 and 74 years were
current users of HRT. On average women started using
HRT at 51 years and continued their use for a rather long
duration (7.8 years on average). It is therefore quite likely
that the proportion of current users among women aged
45–59 years would have been much higher. In contrast, the
prevalence of HRT use is low in the Netherlands, only 13–
19% of middle-aged Dutch women were current users of
HRT during the nineties and the median duration of use
was 2 years [23].
The sharp contrast in prevalence and duration of HRT
use between the Netherlands and Geneva could be a valid
explanation for the changes in breast cancer incidence and
age distribution between the two populations.
In fact, HRT may not only explain the shift in age-inci-
dence, but also the disproportionate increase in lobular
cancer incidence, since many case-control and cohort
studies have demonstrated strong links between HRT and
lobular histology and, to a lesser extent, ductal cancer [18,
19, 30]. Li et al. examined the relation between HRT and
lobular breast cancer and reported a significantly increased
risk of lobular cancer (Odds Ratio [OR] 2.6) but not of
ductal cancer (OR 0.7) among current users of combined
HRT (including oestrogen and progesterone) [29]. Tjonne-
land et al. [20] prospectively investigated the breast cancer
occurrence in a cohort of 29,875 women and found an
increased risk of lobular breast cancer (Hazard Ratio [HR]
3.5) and ductal breast cancer (HR 2.1) among women using
combined HRT. Especially long-term duration of HRT is
associated with an increased risk of invasive lobular cancer.
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Other potential explanations for the disproportionate
increase in lobular cancer in Geneva include increased
diagnostic activity, improvement in diagnostic techniques,
and changes in diagnostic criteria. In the late 1970s the
definition of invasive lobular carcinoma was broadened
after new histologic variants were defined [30, 31]. How-
ever, since then, no major shifts in histological definitions
have taken place. We consider it therefore unlikely that
changes in broadening of histological criteria explain the
differences in histological subtyping between the two
populations occurring during the nineties.
Despite the fact that the sizes of the two study popula-
tions are very different, we are confident of the validity of
our results. In fact, both groups are well defined popula-
tions, derived from two very reliable population-based
cancer registries, and even the smaller population of
Geneva still provided a large number of patients.
Nevertheless, we realize that our ecological study
cannot provide conclusive evidence as to what has
caused the shift in age distribution in breast cancer
incidence in Geneva. Nevertheless, we would like to
conclude that the absence of the shift in age-specific
breast cancer rates in the Netherlands, a country with a
long tradition and high level of implementation of
mammography screening, renders screening a very un-
likely explanation for the incidence changes seen in
many European and North American populations. Given
the important difference in HRT use during the 1990s
between the Dutch and the Geneva populations, it
becomes increasingly likely that HRT could be a key
factor in the change in age distribution of breast cancer.
However, other etiological factors cannot be excluded to
have contributed to the shift in age distribution of breast
cancer.
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